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PCoronary Artery Disease
Once Daily Therapy With Isosorbide-5-Mononitrate
Causes Endothelial Dysfunction in Humans
Evidence of a Free-Radical–Mediated Mechanism
George R. Thomas, PHD,* Jonathan M. DiFabio, MSC,* Tommaso Gori, MD, PHD,†
John D. Parker, MD, FACC*
Toronto, Canada; and Siena, Italy
Objectives The aim of the study was to determine if isosorbide-5-mononitrate (IS-5-MN) 120 mg, taken once daily for 7
days, is associated with evidence of endothelial dysfunction and whether this effect is determined by increased
free radical production.
Background Tolerance to nitroglycerin is associated with increased free radical production and abnormal endothelial func-
tion. To date, no data is available concerning the effect of IS-5-MN, administered in clinically employed dosages,
on endothelial function in humans.
Methods A total of 19 healthy volunteers were randomized in a double-blind fashion to therapy with IS-5-MN (120 mg
once daily) or placebo. After 7 days of treatment, forearm blood flow responses to acetylcholine (Ach; 7.5, 15,
and 30 g/min) and N-monomethyl-L-arginine (L-NMMA; 1, 2, and 4 mol/min) were measured. In a separate
study, after 7 days of therapy with IS-5-MN 120 mg once daily, the responses to Ach were assessed during intra-
arterial coinfusion of vitamin C (24 mg/min) or saline.
Results As compared with placebo, IS-5-MN caused significant blunting of the responses to both Ach (peak responses:
placebo 127  31%; IS-5-MN 52  24%) and L-NMMA (peak responses: placebo 41  5%; IS-5-MN 22  8%).
Vitamin C completely restored the forearm blood flow responses to Ach (peak responses: vitamin C 180  33%;
saline 107  17%).
Conclusions We document for the first time that IS-5-MN impairs endothelial function in humans in vivo. Suggesting a role
of oxygen free radicals, nitrate-induced abnormalities in endothelium-dependent vasomotor responses were re-
versed by the antioxidant vitamin C. (J Am Coll Cardiol 2007;49:1289–95) © 2007 by the American College
of Cardiology Foundation

















aitroglycerin (GTN) and other organic nitrates have been
idely used in the management of cardiovascular disease.
See page 1296
he major clinical limitation of nitrates is the rapid loss of their
emodynamic and anti-ischemic effects during chronic ther-
py, a phenomenon termed tolerance. The etiology of toler-
nce remains incompletely understood and is almost certainly
ultifactorial (1–7). For the past decade, many lines of
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006, accepted October 12, 2006.bservation have documented that sustained nitrate therapy,
articularly with GTN, is associated with increased vascular
roduction of free radicals (8). Multiple mechanisms of this
ncreased production and/or bioavailability of free radical spe-
ies have been described. The “free radical” hypothesis of
itrate tolerance suggests that the primary cause of tolerance is
n increased bioavailability of vascular superoxide radical anion
nd related reactive oxygen species (ROS) (8–11). Sources of
hese ROS might include the mitochondrial respiratory chain,
he nitric oxide synthase, and membrane oxidases (2,3). Such
n increase might lead to tolerance and vascular dysfunction by:
) inactivation of nitric oxide (the active metabolite of organic
itrates); 2) inhibition of the mitochondrial aldehyde dehydro-
enase, the enzyme responsible for the bioactivation of GTN
nd pentaerithrityl tetranitrate (PETN); 3) dysfunction of the
ndothelial nitric oxide synthase; and 4) by causing a series of
vents (such as increased angiotensin II and endothelin-1
ctivity as well as autonomic dysfunction) associated with
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IS-5-MN Therapy Causes Endothelial Dysfunction March 27, 2007:1289–95Increased vascular ROS bio-
availability has implications be-
yond the development of nitrate
tolerance, and it is now recognized
that sustained therapy with or-
ganic nitrates causes important ab-
normalities in vascular function.
Of note, it has been repeatedly
shown that ROS-dependent en-
dothelial dysfunction is associated
with increased cardiovascular mor-
tality and morbidity (12); while it
is unknown whether nitrate-
induced endothelial dysfunction
has the same prognostic implica-
ions, the observation that therapy with GTN causes ROS
roduction and impaired responses to endothelium-dependent
asomotor stimuli both in the resistance and conductance
irculation in humans in vivo (10) does suggest that these
gents could have negative prognostic effects.
To date, experimental evidence documenting that or-
anic nitrate therapy is associated with increased free
adical production and abnormal endothelial function is
ostly limited to the use of GTN in doses associated
ith the development of nitrate tolerance. Recently, a
umber of investigations have suggested that the organic
itrates may differ in terms of their ability to increase
ascular free radical production and cause abnormalities
n endothelial function. For example, animal data have
uggested that therapy with PETN is associated with a
esser increase in ROS production as compared with
TN. These differences in ROS production might ex-
lain why, in humans, as compared with GTN, PETN
id not cause hemodynamic tolerance, was not associated
ith evidence of increased vascular ROS bioavailability,
nd caused less of an impact on endothelial function
13,14). While these considerations seem to favor PETN,
his drug is not commonly prescribed in North America
nd in several European countries, and GTN and
sosorbide-5-mononitrate (IS-5-MN) remain the most
ommonly employed nitrates. To date, there is no human
ata available concerning the effect of IS-5-MN on ROS
roduction or endothelial function. Recently, Muller
t al. (15) found that long-term, eccentric treatment of
abbits with high dose IS-5-MN did not increase vascular
OS production or induce endothelial dysfunction. Fur-
her, IS-5-MN therapy was also found to prevent intimal
esion formation and endothelial dysfunction in rabbits
rone to develop atherosclerosis (16). Given this back-
round, the objective of the current study was to deter-
ine whether IS-5-MN, taken once daily for 7 days (i.e.,
sing a dosing regimen that is clinically employed), is
ssociated with evidence of endothelial dysfunction in the
uman forearm circulation. If IS-5-MN was associated












ROS  reactive oxygen
speciesecond objective of the study would be to determine rhether the antioxidant vitamin C would reverse this
henomenon.
ethods
tudy population. Twenty-six healthy, nonsmoking male
olunteers 18 to 30 years old participated in the study.
efore enrollment, subjects completed a questionnaire de-
ailing their medical history and underwent a brief physical
xamination. None of the subjects were taking any medica-
ions at the time of investigation. Baseline heart rate (pulse
ate) and blood pressure were also measured. All subjects
ere requested to abstain from caffeine on each of the study
ays, and from alcohol and supplemental vitamins for the
uration of the study. The study protocol was approved by
he Mount Sinai Hospital Research Ethics Board. The
bjective of the study and study procedures were explained
o individual subjects, and written informed consent was
btained from all subjects.
tudy protocol. MEASUREMENT OF FOREARM BLOOD
LOW (FBF). Forearm blood flow was measured simulta-
eously in both arms by venous occlusion strain-gauge pleth-
smography (D. E. Hokanson Inc., Bellevue, Washington)
sing techniques previously reported by our laboratory
10,17). Briefly, circulation of the hand was excluded by
nflating wrist cuffs to 200 mm Hg during measurement
eriods. The upper arm cuffs were inflated to 40 mm Hg
nd deflated at 10 s intervals (Hokanson rapid cuff inflator,
. E. Hokanson Inc.), and FBF was recorded as the average
f 5 consecutive measurements. On visit 1, only basal FBF
as measured. On visit 2, FBF was measured at baseline
nd in response to brachial artery infusions of normal saline
nd vasoactive agents as described in detail in the following
ext.
xperiment 1. STUDY DAY 1. Nineteen healthy volunteers
ge between 18 to 30 years participated in this randomized,
ouble-blind placebo-controlled study. After screening (in-
lusive of anamnesis and brief physical examination) for
dmission into the study, standing blood pressure and heart
ate measurements were obtained using an automatic, cali-
rated sphygmomanometer (Critikon Company LLC,
ampa, Florida). The mean of 3 measurements was deter-
ined. Baseline FBF was measured as described in the
receding text. Subjects were then randomized in a double-
lind fashion to receive either a phasic release formulation
f IS-5-MN (Imdur, AstraZeneca Canada Inc., Missis-
auga, Ontario, Canada) 120 mg given once daily (IS-
-MN group; n  10) or placebo (placebo group; n  9).
fter the first dose of study medication, repeat standing
lood pressure and heart rate measurements were taken 3 h
ater. All subjects were instructed to take their study
edication daily at 9:00 AM until the end of the study.
TUDY DAY 2. Subjects returned to the laboratory after 7
ays of continuous therapy with IS-5-MN or placebo.
tanding blood pressure and heart rate measurements were
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March 27, 2007:1289–95 IS-5-MN Therapy Causes Endothelial Dysfunctionhe nondominant arm was measured at baseline and in
esponse to drug infusions. Forearm blood flow was also
easured in the opposite arm using strain gauge plethys-
ography at each measurement time point. The
ndothelium-dependent vasodilator acetylcholine (Ach)
hloride (Novartis Pharmaceuticals, Ontario, Canada) was
nfused at 7.5, 15, and 30 g/min. Subsequently, FBF
esponses to N-monomethyl-L-arginine (L-NMMA) (1, 2,
nd 4 mol/min; Clinalfa AG, Laufelfingen, Switzerland)
ere measured. The infusion rate was kept constant at 0.4
l/min with a precision pump (Harvard Apparatus, South
atick, Massachusetts). Each concentration was infused for
min, and FBF measurements were performed during the
ast 3 min. All responses were evaluated as changes from a
aseline value (normal saline infusion) immediately before
ach drug infusion. Intra-arterial blood pressure was re-
Figure 1 A Schematic Diagram of the IS-5-MN Study Protocol
(A) Diagram of the study protocol to determine the effects of a 7-day isosorbide-5
protocol to determine the effect of vitamin C (vit C) on IS-5-MN–induced changes i
IS-5-MN  isosorbide-5-mononitrate; L-NMMA  N-monomethyl-L-arginine; ROS orded after each infusion (Horizon 2000, Mennen Medical
nc., Clarence, New York) using the average of at least 15
ardiac cycles. Electrocardiogram was monitored continu-
usly. Between different drug infusions, normal saline was
nfused until the flow returned to baseline values. At the end
f the study, the arterial line was removed, all study
edications discontinued, and subjects were discharged
rom the laboratory. A schematic flow of the study protocol
s represented in Figure 1A.
xperiment 2: studies with IS-5-MN and vitamin C. In
separate study, 7 subjects were treated with IS-5-MN 120
g daily for 7 days. Subsequently, subjects returned to the
aboratory at which time the brachial artery was cannulated
nd FBF in the nondominant arm was measured at baseline
nd in response to drug infusions. Forearm blood flow was
lso measured in the opposite arm using strain gauge
nitrate (IS-5-MN) therapy on endothelial function. (B) Diagram of the study
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IS-5-MN Therapy Causes Endothelial Dysfunction March 27, 2007:1289–95lethysmography at each measurement time point. Acetyl-
holine was infused at 7.5, 15, and 30 g/min at a rate of
.4 ml/min. Normal saline was coinfused at a rate of 0.4 ml
uring the Ach infusions. Ten minutes after the completion
f the Ach  saline infusions, vitamin C was infused at a
ate of 24 mg/min for 15 min. This infusion rate, which is
xpected to achieve a local plasma concentration of 1 mg/ml
r 5 mM (i.e., approximately 50 times the normal concen-
ration), has been used in previous studies to demonstrate a
ole of ROS in the pathogenesis of endothelial dysfunction
n patients with cardiovascular disease (12). Subsequently,
hile the vitamin C infusion was continued, Ach was again
dministered at 7.5, 15, and 30 g/min. Each concentration
as infused for 6 min, and FBF measurements were
erformed during the last 3 min. A schematic flow of the
tudy protocol is represented in Figure 1B. All responses
ere evaluated as changes from a baseline value (normal
aline infusion) immediately before each drug infusion.
ata were digitally acquired, and each series of infusions
as given a coded identifier. Analysis was performed off-
ine, in random order, by an investigator blinded to this
ode.
tatistical analysis. All results are expressed as mean 
E. Comparisons between groups for baseline values were
erformed with unpaired t tests. The effect of IS-5-MN on
lood pressure and heart rate was tested using a 2-way
nalysis of variance (ANOVA) with Bonferroni correction.
ll FBF values were compared as the ratio of the infused
ersus the noninfused arm. Differences between groups in
lood flow responses were tested using 2-way repeated
easures ANOVA on the % and absolute changes in FBF
s compared with the corresponding baseline. A value of
 0.05 was set as the threshold for significance. Statistical
nalyses were performed using Sigmastat (Jandel Scientific,
an Rafael, California).
esults
tudy 1. BLOOD PRESSURE AND HEART RATE RESPONSES.
n visit 1, baseline standing heart rate and systolic blood
ressure did not differ significantly between groups (Table 1).
ompared with baseline values, in the IS-5-MN group,
tanding Blood Pressurend Heart Rate Responses to IS-5-MN







Systolic blood pressure, mm Hg
IS-5-MN group 117 2 105 2* 111 2
Placebo group 123 4 120 3 119 4
Heart rate, beats/min
IS-5-MN group 72 3 83 3* 78 3
Placebo group 78 4 79 4 80 3
p  0.05 as compared with baseline and with all data points in the placebo group, analysis of
ariance p  0.05 for the effect of group and of time, p  NS for the interaction.
IS-5-MN  isosorbide-5-mononitrate.tanding blood pressure was significantly lower (p  0.05,
NOVA with Bonferroni correction) and heart rate was
ignificantly higher (p  0.05) at 3 h after the administra-
ion of the first dose. The blood pressure and heart rate
esponses observed in the IS-5-MN group were significantly
ifferent from those observed in the placebo group (signif-
cant group interaction by 2-way ANOVA). On visit 2,
hese hemodynamic effects of IS-5-MN were still evident
ut were no longer statistically significant. Blood pressure
nd heart rate in the placebo group were similar at all time
oints. Intra-arterial drug infusions had no significant effect
n blood pressure and heart rate.
FFECT OF IS-5-MN TREATMENT ON FBF. On visit 1, FBF
as similar between the 2 groups (data not shown). On visit 2,
aseline FBF remained similar between groups, and within
ach group it did not significantly differ from the values
btained on visit 1.
ESPONSES TO ACH INFUSIONS. The intra-arterial infusion
f Ach caused a dose-dependent increase in FBF in both
roups (p  0.05, effect of the three levels of infusion rate,
Figure 2 FBF Responses to Ach Infusion
p  0.05 for the effect of treatment group, 2-way analysis of variance. Ach 
acetylcholine; FBF  forearm blood flow; IS-5-MN  isosorbide-5-mononitrate;
I/N  ratio of forearm blood flow, infused to noninfused arms.
BF Responses: Ratio of Infused to Noninfused Arm
Table 2 FBF Responses: Ratio of Infused to Noninfused Arm
Infusions Placebo IS-5-MN
Saline 1.56 0.17 1.57 0.24
Ach 7.5 g/min 2.29 0.31 1.96 0.35
Ach 15 g/min 2.87 0.59 1.91 0.35
Ach 30 g/min 3.58 0.70 2.49 0.69
Saline 1.81 0.20 1.53 0.34
L-NMMA 1 mol/min 1.74 0.26 1.41 0.31
L-NMMA 2 mol/min 1.26 0.16 1.46 0.29
L-NMMA 4 mol/min 1.09 0.15 1.06 0.13
alues are mean SE and are expressed as the ratio of the infused to the noninfused arms. *p
.05 between groups, 2-way analysis of variance, % change, and delta change from saline infusion.
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March 27, 2007:1289–95 IS-5-MN Therapy Causes Endothelial Dysfunction-way ANOVA) (Table 2, Fig. 2). When compared be-
ween groups, the responses to each Ach step were signifi-
antly blunted in the IS-5-MN group as compared with
lacebo (group effect, p  0.05, 2-way ANOVA). Showing
hat this difference was consistent through the 3 infusion
ates, there was no statistically significant interaction be-
ween group and infusion level (p  0.3, 2-way ANOVA).
n the placebo group, during infusion of the highest
oncentration of Ach, FBF increased by 127  31% as
ompared with baseline, whereas in the IS-5-MN group, it
ncreased by only 52  24% (p  0.05).
ESPONSES TO L-NMMA INFUSIONS. N-monomethyl-L-
rginine caused a dose-dependent vasoconstriction in both
roups (p  0.05, 2-way ANOVA) (Table 2, Fig. 3). In the
S-5-MN–treated group, the decreases in FBF in response
o the 2 mol and 4 mol/min infusions were significantly
lunted as compared with the placebo group (p  0.05 for
roup effect, p  0.05 for the interaction of group and
nfusion rate). At the highest infused concentration of
-NMMA, the decrease in FBF was 41  5% in the
lacebo-treated group and 22 8% in the IS-5-MN group.
tudy 2. THE EFFECT OF VITAMIN C COADMINISTRATION
N IS-5-MN–INDUCED CHANGES IN FBF. In the subjects who
ad been treated with IS-5-MN 120 mg once daily for 7
ays, intra-arterial infusion of vitamin C (in a dosage
reviously shown to reverse endothelial dysfunction in
atients with cardiovascular disease [12]) significantly in-
reased FBF responses to Ach as compared with Ach alone
p  0.05 for vitamin C vs. saline coinfusion). This
ifference did not depend on the infusion rate of Ach (p 
.05 for the effect of the infusion rate, p  NS for the
nteraction of coinfused drug and Ach infusion rate) (Table
, Fig. 4). During coinfusion of vitamin C, FBF increased
y 180  33% in response to the highest infused concen-
Figure 3 FBF Responses to L-NMMA Infusion
p  0.05 for the effect of treatment group, 2-way analysis of variance.
L-NMMA  N-monomethyl-L-arginine, other abbreviations as in Figure 2.ration of Ach. In contrast, during coinfusion of saline, FBF
ncreased by only 107  17% in response to the highest
nfused concentration of Ach.
iscussion
ver the past decade there have been several reports
ocumenting that GTN therapy has adverse effects on
ndothelial function. Our laboratory and other groups have
hown that long-term treatment with GTN causes abnor-
alities in nitric oxide synthase and endothelial function
10,17,18). Nitric oxide synthase dysfunction associated
ith GTN therapy has been attributed to uncoupling of the
nzyme in the setting of increased vascular production of
ree radical species.
Increased vascular oxidative stress secondary to prolonged
TN exposure is well documented and with a number of
ources described, including xanthine oxidase (8,19), nico-
inamide adenine dinucleotide oxidase (20), the mitochon-
rial electron transport chain, cytochrome P450 oxidase
21), as well as nitric oxide synthase itself (9–11). Of
mportance, this increased vascular free radical bioavailabil-
ty has implications beyond the development of nitrate
olerance as ROS oxidizes carbohydrates, lipids, proteins,
nd DNA (22–25) and are thus capable of disrupting
Figure 4 FBF Responses to Ach and Vitamin C Infusion
p  0.05 for the effect of vitamin C versus saline coinfusion, 2-way analysis of
variance. Abbreviations as in Figure 2.
BF Responses: Ratiof Infused to Noninfused Arms




Saline 1.1 0.06 1.0 0.10
Ach 7.5 g/min 1.4 0.17 1.8 0.22
Ach 15 g/min 1.8 0.20 2.1 0.31
Ach 30 g/min 2.2 0.23 2.8 0.31
alues are mean SE and are expressed as the ratio of the infused to the non-infused arms. *p
.05 between groups, 2-way analysis of variance, % change, and delta change from saline infusion.
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IS-5-MN Therapy Causes Endothelial Dysfunction March 27, 2007:1289–95iochemical homeostasis and inducing biological injury.
ccordingly, studies in both humans and animals have
hown that prolonged exposure to GTN induces abnormal-
ties in the function of several enzyme systems as well as
eurohormonal activation and impaired nitrate biotransfor-
ation. Although the relative contribution of these abnor-
alities to the induction of nitrate tolerance is unknown,
hey appear to be caused and result in increased bioavail-
bility of ROS.
It is now known that prolonged exposure to GTN causes
ndothelial dysfunction in healthy subjects (17) and in
ubjects with risk factors for vascular disease (18,26). Im-
ortantly, there is also experimental evidence to suggest
here may be within-class differences in terms of the impact
f organic nitrates on endothelial function and nitrate
olerance development. For example, we have previously
hown that therapy with pentaerythrityl tetranitrate, which
as antioxidant properties, is associated with less severe
bnormalities in human endothelial function as compared
ith GTN, and it does not cause tolerance (13,14). As well,
here are within-class differences in terms of the site of
iotransformation: while GTN and PETN are activated
ithin mitochondria, the site of IS-5-MN biotransforma-
ion is yet unknown (27). Finally, there are also reports that
ertain organic nitrates, in experimental conditions, can
ave protective vascular effects. For example, one group has
ypothesized that nitrate-derived nitric oxide might have
rotective effects that are similar to those of endogenous
itric oxide. In particular, using a rabbit model of acceler-
ted atherogenesis, Muller et al. (15,16) recently demon-
trated that long-term treatment with IS-5-MN retards
ntima-media thickening, prevents the development of en-
othelial dysfunction, and is associated with a decrease in
ascular ROS production. In sum, while evidence exists that
TN can cause ROS production and endothelial dysfunc-
ion, PETN seems to be devoid of these effects, and animal
tudies—which need human confirmation—show that IS-
-MN might protect from hypercholesterolemia. To date,
here have been no studies examining the impact of the
ost commonly employed nitrate (i.e., IS-5-MN) on en-
othelial function in humans in vivo.
ummary of our findings. The results of the current
uman study suggest that the administration of a phasic-
elease formulation of IS-5-MN, given once daily, is asso-
iated with the development of pronounced endothelial
ysfunction. Of note, this is the first demonstration of an
dverse effect observed by using a clinically employed dosing
egimen of IS-5-MN. Consistent with our prior studies of
ransdermal GTN, the blunted flow responses to Ach, an
ccepted marker of endothelial dysfunction, were associated
ith very abnormal responses to the administration of
-NMMA. The latter finding suggests that the abnormal
esponses to Ach are caused, at least in part, by abnormal-
ties in nitric oxide synthase function as previously demon-
trated for GTN (4,17). In a second set of experiments,
e prove that oxidative stress plays a major role in the oS-5-MN–induced development of endothelial dysfunc-
ion. Collectively, these data provide evidence suggesting
hat IS-5-MN, in a clinically employed dosage, stimulates
ascular production of ROS and causes endothelial
ysfunction.
These data are in agreement with those of Sekiya et al.
28), who showed that isosorbide dinitrate, of which IS-
-MN is a metabolite, impairs endothelium-dependent
ilation and worsens intima-media thickness in patients
ith cardiovascular disease. Furthermore, we provide the
rst human evidence suggesting that this vascular dysfunc-
ion is secondary to increased ROS production as it is
ompletely reversed by the coadministration of intra-arterial
itamin C. The explanation for the differences between our
ndings and those of the animal reports from Muller et al.
16) is not entirely clear but might reside in the differences
n species, experimental model (healthy volunteers vs. hy-
ercholesterolemic animals), nitrate dosing, as well as in the
ascular beds studied. Whatever these differences, we show
hat, in humans, a dosage of IS-5-MN that is commonly
mployed, and that is believed to be free of nitrate tolerance,
auses (ROS-mediated) endothelial dysfunction.
Of note, our study involved normal volunteers rather than
atients with cardiovascular disease, and we recognize that
ur results may not necessarily be extrapolated to the clinical
etting. However, since endothelial vasomotor responses are
lready blunted in most patients with coronary artery
isease, the effect of interventions that lead to further
ndothelial dysfunction (such as nitrate therapy) would be
ery difficult to study with the model of endothelium-
ependent vasomotor responses that we employed. While
his limitation is recognized, the authors would like to
mphasize that, in this study, nitrates induced severe,
OS-mediated, endothelial dysfunction in individuals with
ntact ROS scavenging capacities.
linical relevance of our findings. Our findings have
mportant clinical implications. Isosorbide-5-mononitrate is
he most commonly used long-acting nitric oxide donor in
linical practice (29). The fact that it can cause profound
ndothelial dysfunction in healthy subjects is both surprising
nd a cause for concern given the traditional concept that
itric oxide donors might have beneficial effects in the
etting of decreased nitric oxide bioavailability (30). Our
ndings with IS-5-MN are similar to our previous obser-
ations with GTN; therapy with GTN causes important
bnormalities in endothelial function in forearm resistance
essels, epicardial coronary arteries, as well as in peripheral
onduit arteries (14,18). Therefore, it seems that commonly
sed organic nitrates, despite a (blunted) residual hemody-
amic and symptomatic effect, cause abnormalities in endo-
helial function, which might have clinical relevance during
ustained therapy. Furthermore, our data suggest that
itrate-induced production of ROS, and subsequent endo-
helial dysfunction, associated with nitrate administration
an be prevented by concurrent administration of an anti-
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March 27, 2007:1289–95 IS-5-MN Therapy Causes Endothelial Dysfunctionrugs. These data agree with observations from A-HEFT
African-American Heart Failure Trial) (31), where the
ombination of IS-5-MN and hydralazine (which is more
eliably absorbed after oral administration as compared
ith vitamin C and has antioxidant properties [32])
mproved the clinical outcome of patients with chronic
ongestive heart failure. Taken together, these consid-
rations emphasize the need for more clinical data
oncerning the impact of organic nitrates ( antioxidant
herapy) on long-term clinical outcome and the process of
therogenesis.
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